Fuzionaire DX
1 known investors
Fuzionaire Theranostics develops radiopharmaceuticals for oncology using its HetSiFA silicon (SiFA) chemistry platform, creating chemically matched fluorine-18 PET diagnostic and radioligand therapy pairs. Its lead program, FTX-426, targets GRPR-expressing solid tumors such as prostate and breast cancer.
BiotechDeep TechMedical Devices
Investors · 1
Frequently asked questions
- What does Fuzionaire DX do?
- Fuzionaire Theranostics develops radiopharmaceuticals for oncology using its HetSiFA silicon (SiFA) chemistry platform, creating chemically matched fluorine-18 PET diagnostic and radioligand therapy pairs. Its lead program, FTX-426, targets GRPR-expressing solid tumors such as prostate and breast cancer.
- Who are Fuzionaire DX's investors?
- Fuzionaire DX's investors include Emles Venture Partners.